The Manila Times

Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of ...

Zovegalisib has received FDA Breakthrough Therapy designation for the Phase 3 ReDiscover-2 trial population. CAMBRIDGE, Mass.